For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a true change. These innovative therapies protect the transthyretin protein, halting its destructive build-up and alleviating the impact of the illness. Individuals are now seeing positive outcomes in the